2-Chloro-3-(4-methylpiperazin-1-yl)pyrazine

Catalog No. :
ACMCHY658
CAS No. :
313657-05-5
Molecular Formula :
C9H13ClN4
Molecular Weight :
212.68

IUPAC Name:2-chloro-3-(4-methylpiperazin-1-yl)pyrazine

2-Chloro-3-(4-methylpiperazin-1-yl)pyrazine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg95%$182.00Login to see priceInquiryInquiry
1g95%$481.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-Chloro-3-(4-methylpiperazin-1-yl)pyrazine
IUPAC Name2-chloro-3-(4-methylpiperazin-1-yl)pyrazine
MDL No.MFCD09999198
Molecular FormulaC9H13ClN4
Molecular Weight212.68
SMILESCN1CCN(C2=NC=CN=C2Cl)CC1
InChI KeyQKGVXLAHFBSFHO-UHFFFAOYSA-N
Synonym1-(3-CHLORO-2-PYRAZINYL)-4-METHYLPIPERAZINE;2-Chloro-3-(4-Methylpiperazin-1-yl)pyrazine;2-Chloro-3-(4-methyl-1-piperazinyl)pyrazine;Pyrazine, 2-chloro-3-(4-methyl-1-piperazinyl)-
CAS No.313657-05-5

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACMCHY658 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACJACD865 route compound structure diagram
    ACJACD86534352-59-5 In Stock
  2. Plus
  3. ACQULK639 route compound structure diagram
    ACQULK6394858-85-9 In Stock
  4. Then
  5. ACMCHY658 route product structure diagram
    ACMCHY658313657-05-5
Inquiry

2. ACMCHY658 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACKSZQ125 route compound structure diagram
    ACKSZQ12593556-88-8 In Stock
  2. Plus
  3. ACJACD865 route compound structure diagram
    ACJACD86534352-59-5 In Stock
  4. Plus
  5. ACQULK639 route compound structure diagram
    ACQULK6394858-85-9 In Stock
  6. Then
  7. ACMCHY658 route product structure diagram
    ACMCHY658313657-05-5
Inquiry

Comments (0)